EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The absence of IL17A favours cytotoxic cell function and improves antigen‐specific immunotherapies in pancreatic adenocarcinoma

Giorgia Tiberi, Alessandro Scagliotti, Claudia Curcio, Ermes Candiello, Paula Ariadna Diez Villegas, Silvia Brugiapaglia, Gianluca Mucciolo, Cecilia Roux, Giancarlo Castellano, Roberta Curto, Maddalena Arigoni, Raffaele A Calogero und 6 weitere

Clinical and Translational Medicine · 2025

DOI: 10.1002/ctm2.70442 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2025. Verfasst von Giorgia Tiberi und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy. Hauptthemen laut MEDLINE: Interleukin-17, Pancreatic Neoplasms, Immunotherapy, Adenocarcinoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Associazione Italiana Ricerca sul Cancro, Fondazione Compagnia di San Paolo-PoC Instruments, Italian Ministry of Foreign Affairs and International Cooperation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims The pancreatic tumour microenvironment (TME) is a complex ecosystem where tumour cells, cancer‐associated fibroblasts and immune cells interact, often in ways that contribute to tumour growth. The role of interleukin (IL17)A in pancreatic cancer progression is now more defined, and it is known to sustain a pro‐tumoural microenvironment and inhibit the immune response. Here, we explore the effect of combining IL17A depletion with a cancer vaccine to enhance anti‐tumour immunity.

Methods

We used genetically engineered mice proficient or deficient in IL17A, and orthotopically injected mice with pancreatic tumour cells depleted or not in IL17A, to examine the vaccine effects on tumour growth and immune responses. Both humoral and cellular immune responses were analysed following vaccination in IL17A‐deficient and control mice.

Results

Mice lacking IL17A—either genetically or through pharmacological depletion—exhibited prolonged survival and smaller tumours, compared to vaccinated controls. Vaccination in IL17A‐deficient mice significantly increased the influx of immune cells, including Natural Killer (NK) and effector/memory CD8 T cells, which displayed higher cytotoxic activity. CD8 T‐cell depletion in these models notably reduced vaccine efficacy, underscoring the essential role of these cells. NK cell depletion in untreated models further demonstrated NK cells’ critical function in controlling tumour growth when IL17A was absent. Overall, IL17A depletion enhanced both antigen‐specific humoral and cellular immune responses, indicating a shift towards a more robust and responsive immune environment.

Conclusions

Our findings reveal that the absence of IL17A in the pancreatic TME reprograms it into a more immune‐supportive environment, favouring the recruitment of effector/memory immune cells upon vaccination. This approach paves the way for novel therapeutic combinations in pancreatic cancer, where IL17A depletion may boost both immunotherapy efficacy and anti‐tumour responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-17Pancreatic NeoplasmsImmunotherapyAdenocarcinomaAnimalsMiceTumor MicroenvironmentCancer VaccinesHumansMice, Inbred C57BL

Stichwörter der Autor:innen

IL17Acancer vaccinehumoral responsepancreatic cancertumour immune microenvironment

Substanzen

Interleukin-17Cancer Vaccines

Autor:innen und Institutionen

  • Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
  • Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Dipartimento di Oncologia ed Emato-Oncologia, University of Milan, Milan, Italy.
  • Pathology Unit, Department of Medical Sciences, University of Torino, AOU Città Della Salute E Della Scienza Di Torino, Turin, Italy.
  • Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, Immunos, Singapore, Republic of Singapore.
  • Molecular Biotechnology Centre "Guido Tarone,", University of Torino, Turin, Italy.

ORCID-Profile: Paola Cappello

Förderung

  • Associazione Italiana Ricerca sul Cancro
  • Fondazione Compagnia di San Paolo-PoC Instruments
  • Italian Ministry of Foreign Affairs and International Cooperation
  • 1st Italy-Singapore Science and Technology Cooperation
  • Progetti di Rilevante Interesse Nazionale-PRIN
  • Fondazione Onlus Ricerca Molinette
  • Associazione Nastro Viola
  • Fondazione Nadia Valsecchi

Zitieren

APA

Tiberi, G., Scagliotti, A., Curcio, C., Candiello, E., Villegas, P. A. D., Brugiapaglia, S., Mucciolo, G., Roux, C., Castellano, G., Curto, R., Arigoni, M., Calogero, R. A., Barutello, G., Bolli, N., Papotti, M. G., Adriani, G., Novelli, F., & Cappello, P. (2025). The absence of IL17A favours cytotoxic cell function and improves antigen‐specific immunotherapies in pancreatic adenocarcinoma. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.70442

Vancouver

Tiberi G, Scagliotti A, Curcio C, Candiello E, Villegas PAD, Brugiapaglia S, et al. The absence of IL17A favours cytotoxic cell function and improves antigen‐specific immunotherapies in pancreatic adenocarcinoma. Clinical and Translational Medicine. 2025. doi:10.1002/ctm2.70442

BibTeX
@article{Tiberi2025,
  author = {Tiberi, Giorgia and Scagliotti, Alessandro and Curcio, Claudia and Candiello, Ermes and Villegas, Paula Ariadna Diez and Brugiapaglia, Silvia and Mucciolo, Gianluca and Roux, Cecilia and Castellano, Giancarlo and Curto, Roberta and Arigoni, Maddalena and Calogero, Raffaele A and Barutello, Giuseppina and Bolli, Niccolò and Papotti, Mauro Giulio and Adriani, Giulia and Novelli, Francesco and Cappello, Paola},
  title = {The absence of IL17A favours cytotoxic cell function and improves antigen‐specific immunotherapies in pancreatic adenocarcinoma},
  journal = {Clinical and Translational Medicine},
  year = {2025},
  doi = {10.1002/ctm2.70442}
}
Kostenlos starten →